International News 2r123y

Milan (Italy) – Marchesini Group, a leader in packaging machinery for the pharmaceutical and cosmetics industry, will be exhibiting at the edition of Pharmintech powered by Ipack-Ima, the exhibition dedicated to innovations and solutions in processing and packaging, being held in Milan, Italy from May 27 to 30, 2025.

The trade fair will be an opportunity for Marchesini Group to engage in discussions and networking, looking towards 2025 with cautious optimism after the good results of 2024, which saw consolidated turnover of over 600 million Euros. “We are satisfied with the results achieved last year; the Group has continued to grow steadily,” commented Valerio Soli, CEO of Marchesini Group. “We aim to reach a billion Euros of revenue in the medium-short term through further acquisitions and business opportunities in new geographical areas. With the goal of offering increasingly complete and integrated lines to our customers, we have decided to showcase in Milan some machine models which are capable of packaging various types of drugs and cosmetics, without neglecting our digital services featuring artificial intelligence.”

Solutions on show at stand A26 B25 – Hall 2

At Pharmintech powered by Ipack-Ima, the Group will be exhibiting a wide range of solutions for the pharmaceutical and cosmetics industry: from processing machines to primary packaging of solid, liquid, and powder products, with a corner dedicated to digital technologies.

With regard to the pharmaceutical business, there will be two main focuses: on the one hand, solutions for powder filling, which the Group has been emphasizing recently thanks to the integration of the MAR brand; on the other hand, process technologies with the Dumek brand, increasingly oriented towards pharmaceutical production and compliance with sector regulations.

On display at the stand will be a powder filling machine with vacuum-pressure disk filling technology and 100% IPC, and a vacuum turboemulsifier for processing liquid or cream products, featuring an interactive system that shows off the various production phases.

There will also be a monoblock for blister packaging integrated with the new alternating cartoner, capable of handling a wide range of formats at a maximum speed of 150 pieces per minute. Rounding off the offering will be a selection of Dott. Bonapace branded laboratory machines, including a complete line for filling, cooling, and sealing ovules and suppositories; a two-channel system for counting and filling bottles with tablets, capsules, and pills; as well as a capsule filler and a rotary tablet press.

As regards the cosmetics sector, on the other hand, the Beauty Division will be showcasing a line for tubes, first filled and closed by an Axomatic tube filler, then placed in cartons by the V2 engineering horizontal alternating motion cartoner. Also on display will be a line developed through the collaboration between the Vibrotech and Axomatic brands, consisting of a robotic feeding system perfectly integrated with a linear filling and capping machine for stable bottles.

The technologies of the Digital division (including predictive maintenance, the Customer Portal, and augmented reality format change) will also be featured, along with vision systems from SEA Vision, celebrating its 30 years of experience in the sector at the stand.

Waiblingen (), April 2, 2025 – Syntegon, a strategic partner of the pharmaceutical and food industries, is continuing its successful development and preparing for the next phase of its growth strategy. With the sale of its former site in Waiblingen to Andreas Stihl AG & Co. KG, and the planned relocation of its production and istration activities to Fellbach and Bad Cannstatt (Stuttgart) this year, Syntegon is setting the ideal conditions for further growth.

Hundred-gram scale synthesis enables discovery and early development for conjugated drug development

Luar es un un laboratorio farmacéutico que ofrece servicios de elaboración para terceros. Cuenta con una amplia gama de servicios de producción y una planta farmacéutica habilitada para:

With cases of avian influenza A (H5N1) continuing to rise among cattle and humans in the US, scientists and government health officials are preparing for the potential of the virus adapting to enable human-to-human transmission. While there is no evidence yet that H5N1 could spread between humans, pandemic preparedness is essential, and mRNA vaccines offer great potential to mitigate a future pandemic, says GlobalData, a leading data and analytics company.

The inaugural Pharma Logistics Winter University, co-founded by the Department of Health – Abu Dhabi, Etihad Cargo, Pharma.Aero, the University of Antwerp, and Khalifa University of Science and Technology, offers an immersive five-day programme in Abu Dhabi, bridging academic learning with practical application to cultivate future global leaders in pharmaceutical logistics.

With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a 9.6% compound annual growth rate (CAGR) from $13.5 billion in 2022 to $33.7 billion in 2032 across the seven major markets (7MM*), forecasts GlobalData, a leading data and analytics company.

AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its primary and secondary endpoints, suggesting that tavapadon has the potential to become a prominent treatment within the dopamine agonist market, says GlobalData, a leading data and analytics company.

Coutances, – [December 12, 2024] – Unither Pharmaceuticals, a global leader in sterile liquid pharmaceutical formulations, has successfully launched the first commercial batches of Preservative-Free Multidose (PFMD) ophthalmic products at its Laboratoire Unither Coutances site in Normandy, .

Carmot acquisition propels Roche to forefront of obesity drug leadership, finds GlobalData

In a significant move in December 2023, Roche completed the acquisition of the US-based company Carmot Therapeutics in a deal worth $2.9 billion. This strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. This acquisition positions Roche on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others, according to GlobalData, a leading data and analytics company.

GlobalData’s Technology Foresights model recognizes GLP-1 analogues as a high-impact innovation, with accelerating patent trends and other markers indicating their near-term impact. Notably, leaders in this space, like Novo Nordisk and Eli Lilly, have experienced significant success, with share prices surging over 20% in 2023 year on year due to the sales of their respective GLP-1 agonist brands, Wegovy and Mounjaro.

The Technology Foresights model also identifies over 70 companies, including early-stage ventures, actively developing innovative products utilizing GLP-1 analogues. The model further suggests that these molecules, primarily targeting obesity and type 2 diabetes, are also being explored for applications in neurological disorders and NASH type Hepatitis.

Sourabh Nyalkalkar, Practice Head of Innovation Products at GlobalData comments: “As a major player in the pharmaceutical industry, Roche has traditionally focused its research and development (R&D) efforts on cancer research, diagnostics, and gene therapies, as evidenced by the 120+ innovation areas tracked for Roche on the Technology Foresights model. However, innovations in lifestyle disorders, such as GLP-1 analogues, were not a key focus until this recent acquisition.”

On the other hand, Carmot Therapeutics, a privately held company, centred its innovation portfolio almost entirely on GLP-1 agonists. Two out of its four molecules have received positive responses in Phase I clinical trials, positioning Carmot among the leaders in the field of GLP-1 analogue innovation, as identified by GlobalData’s proprietary framework.

Sourabh concludes: “Roche’s well-timed move aligns with the resounding success of GLP-1 agonists like Ozempic, Wegovy, and Mounjaro. The shift in Roche’s position is evident on the innovation leadership map. This move also signals a potential trend, suggesting that other major pharmaceutical players with a strong market presence may be actively seeking targets with robust innovation portfolios in GLP-1 analogues. The Technology Foresights model emerges as a valuable tool for evaluating potential targets in this evolving landscape.”